OBJECTIVE: To observe the effect of the polyglycol (PEG) modification of trimeric ? peptide(?3) on it’s anti-metastasis ability. METHODS: Using adhesion test to study the effects of ?3 and ?3-PEG on the adhesion of tumor cells to FN. Using artificial basal membrane to study the effects of ?3 and ?3-PEG on the invasion and recombination of basal membrane of tumor cells. RESULTS: Comparing to negative control,?3 and ?3-PEG could both inhibit the adhesion of SMMC-7721 and HCCLM6 tumor cells to FN with time-dependently(P

Objective To Study the correlation factors for diabetes pathogenesis of Uygur Nationality in Urumuqi.Methods A cluster sampling was done in 1002 Uygur people aged 25 to 74 years in a part of working units and living area in Urumuqi.All the people received 75g oral glucose tolerance test.Waist and hip circumference,blood pressure,height and body weight were measured.A questionnaire involved in the family history,diet,physical activity and the expenditure on diet was taken.Results(1)63% of the people was male,while 37% was female in our study.The constituent ratio of age was as following:25y～,23.08%;35y～,36.90%;45y～,19.64%;55y～,14.86%and 65y～,5.51%.(2)The prevalence of DM in the study was 14.69%,the abnormality of glucose metabolism was 29.89%.(3)The correlation factors of diabetes were family history of diabetes(OR 0.59),age(OR 0.83),high blood pressure(OR 0.912),waist-to-hip ratio(OR 3.851)and financial spending on diet(OR 5.279) in logistic regression analysis.Conclusions Diabetes-correlated factors are high financial spending on food especially meat products and little cellulose intake,high waist-to-hip ratio.To decrease the prevalence rate of diabetes in Uygur nationality,it is most important to change the diet habit and decrease intra-abdominal fat deposition

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin's lymphomas (NHLs). MCL comprises distinct subtypes with different pathological characteristics and clinical features. However, MCL remains incurable by intensified first-line regimens con-taining cytarabine and involving consolidation with high-dose therapy and autologous stem cell transplantation. Recently discovered somatic mutations and aberrant intracellular signaling pathways have been demonstrated to play an essential role in the pathogenesis of MCL. The related novel therapeutics, such as Btk inhibitors, PI3K inhibitors, and immune modulators, have exhibited promising ther-apeutic effects on untreated or even relapsed/refractory MCL. The development of an efficient combination therapy is urgently need-ed to improve the survival of MCL patients in the future.

Rituximab in the combination of CHOP regimen has been widely used as the standard treatment of several kinds of B cell non-Hodgkin lymphoma (B-NHL),but there are still about 1/3 of the late B-NHL patients become primary and secondary resistant to the drug.Recently,many translational research progress in malignant lymphoma promoted the development of promising candidate drugs for the treatment of lymphoma.The advances in translational research field were summarized in this manuscript.

Chronic Disease ; therapy ; Drugs, Chinese Herbal ; therapeutic use ; Heart Failure ; drug therapy ; Humans ; Medicine, Chinese Traditional

Female ; Humans ; Maternal Health Services ; Maternal Mortality ; Pregnancy

Anticoagulants ; therapeutic use ; Atrial Fibrillation ; complications ; Humans ; Thromboembolism ; etiology ; prevention & control

Tremendous success has emerged in chimeric antigen receptor (CAR)-T cell therapy over the past few years, especially in leukemia and lymphoma. The first CAR-T cell product might be available in America in 2017 due to the emergence of the critical results. This paper focused on the key data presented at the 58th American Society of Hematology Annual Meeting.

Objective:To investigate and analyze the rational use of anti-tumor immune enhancement drugs in our hospital. Meth-ods:The annual use data of anti-tumor immune enhancement drugs in our hospital in 2015 were collected, and then statistically ana-lyzed and evaluated combing with the medical history information. Results: There were 12 varieties and 19 specifications of adjuvant anti-tumor immune enhancement drugs in our hospital, which accounted for 15. 87% of the total sum. Totally 25 481 patients used ad-juvant anti-tumor immune enhancement drugs, which occupied 29. 84% of the total medicine afford. The adjuvant anti-tumor immune enhancement drugs showed lots of irrational use in clinics, and the main irrationity was overuse and off-label use. Conclusion: It is necessary to strengthen prescription evaluation for anti-tumor immune enhancement drugs, which needs controlled and rational use.